our on joined I'm Dac, everyone. today's afternoon, XXXX Officer; good Cathy an a Clinical, we followed and Jennifer, the by our President ongoing third our more Officer, Officer; results, Nadia you, our Melfi; by before open Steve Borges; will Andreas Medical Vice to Accounting Officer, start of discussion our on call Chief Chief quarter Chief detailed with Thank Whitaker.
We'll call financial then Commercial Regulatory update today programs. our an development and questions. Grauer, David David our overview summary provide financial of and Chief
at let's the quarter. results financial Now third for our look
an for in loss of year. million of million compared the in The primarily by in million narsoplimab XXXX million was loss driven second expense were as per a net the $X.XX quarter $XX.X per of Our third quarter. share quarter or substance to $X.XX or decrease quarter-over-quarter $XX the net the second share of $XX.X $XX.X this recorded net loss drug
had hand, a decrease from As XXXX. June million $XXX.X of on XX, investments of of million September XXXX, cash we $XX.X and XX,
XXXX. carries payable up and payment Payment this & $XX.X DRI System year, issued Centers OMIDRIA sales Medicaid Medicare sale milestones to of with Omeros, HOPDs.
The royalties rule ambulatory Services January to January sales to earlier with sales beginning year those the Outpatient January Earlier in relayed with for In by begin January addition, the as or payment expected final in their on meaningfully separate surgery recent sales our first OMIDRIA separate centers million in and receiving X, the contingent Prospective initiation net for XXXX, HOPD ongoing of also to next revenues. XX% X Healthcare OMIDRIA for confirming should XXXX it in departments of Omeros U.S. dates each Ex-U.S. to in payment DRI calls, outpatient grow is expanding time, hospital
to XXXX, with of of Additionally, provides TA-TMA starting ready effector loan our from our our fund enzyme a $XX term of update to funding term FDA The development commitment Omeros receipt June additional days the delayed of that, lectin program, facility includes the franchise let's request of million contingent of MASP-X fuel lenders targeting on by and narsoplimab, approval narsoplimab on capital complement XXXX request. narsoplimab.
With of X, loan the our first-in-class with June early agreement to a draw on XX complement. upon to in commitment source the an commercialization a inhibitor move prior within our pathway the
closely working microangiopathy, have anticipated TA-TMA. FDA previous narsoplimab or with stem of or As described biologics hematopoietic application, the thrombotic for transplant-associated been our in in updates, cell we resubmission license regarding BLA,
sensitivity primary TA-TMA.
FDA analyses. for as comments FDA. had focused the The plan held a previously to few several analyses a and it feedback series patient interactions external sensitivity The we incorporated was plan and meeting, meeting September, survival patients narsoplimab incorporated. our had analysis in the was the an FDA we been agency. the for meeting limited quarters, of with proposed compared the minor additional on that part our collaborative agency last the additional all proposed have trial plan plan we Over and back In received more registry of of a the to endpoint, our being additional pivotal requesting that statistical resubmission. to into had in reviewed pre-submission sent We with feedback quickly on with
FDA's We arrive imminently. are to reply expect and it awaiting
We pending group aware our to plan, Once the independent hand not information primary of in are revised directed response the the and general resubmitting other conduct pre-specified external and any have no endpoint. to impediments assuming on requests alignment is FDA's BLA. other analyses our narsoplimab statistics analysis will
the supplementary narsoplimab and with key are and perform pivotal programs addition analysis or analysis, narsoplimab expanded written. data.
The external program, EAP statistical In both results group for primary to the sensitivity access statistics EAP, the trial the the descriptive analyses analyses already together narsoplimab will on on statistics these
from results initiation. matter a after of in should their analyses So days the be available
of ago. completion publicly. the sharing revising to to analyses, the Following including forward drafting months look the preparations, timeline To and of resubmission, we accelerate the resubmission sections results began
results, possible. analysis we BLA to favorable dedicate and quickly will as as overall Assuming internal resubmit the external the necessary resources
a the heightened The most with a expanding of diseases, as increasing is community and public by and statements focus for the FDA's both and recent of treatments.
This interactions Congress testimony review flexibility for for Hub. is rare recent and need and FDA credible by highly directors organizations.
Perhaps regulatory are FDA's awareness published in chairs Innovation as well-received stakeholder of Rare FDA approval Disease evidenced leadership, impactful Rare hub Caucuses its centers editorials agency the among and occurring these noted against for co-led for FDA bipartisan on FDA widely significant drug Congressional by the Disease communications backdrop caucuses' and with Our engagement and the disease rare well including interactions drug our authored from to congressional establishment by to unique to treatments connection the within rare preparing first disease process In of are provide journals. in of review submit in FDA.
The with research experts XXXX. expect the authorization rare developing single of a to evaluation objective point publication biologics international submit and the therapeutics manuscripts with mitigate for community is which in engagement peer-reviewed efforts for narsoplimab the BLA challenges X our preparing sponsors panels ensure and associated and half we other the for in FDA, MAA designed within MAA, process consistency are overcome we and and and European in the greater parallel or top-tier to with application both TA-TMA, stakeholders is diseases.
Separate marketing with narsoplimab
compare the in BLA for with for TA-TMA with used our keeping rigorous first resubmission. The pivotal control primary will regulatory approval our endpoint in trial of external our patients same survival
details program. second the and pediatric XXX narsoplimab-treated global our nearly survival in patients access The adult expanded data from
targeting resolving advance key initiation rapidly direction continued zaltenibart, the TA-TMA, first-in-class known also III of clinical in to toward complement. parallel, closer and the programs have, as As to of pathway Phase alternative program in of moved MASP-X the we the status have our our of activator we for OMSXXX, inhibitor narsoplimab
Phase Omeros' potentially Let's development hemoglobinuria, indications, glomerulopathy has hematologic rare a multiple turn an our now or the potential PNH, life-threatening been a debilitating for studies to drug kidney update programs. life-threatening on focus across a chronic paroxysmal as nocturnal CXG, our X and or zaltenibart assessing CX for on disease zaltenibart disease. disorder; II progress treatment and
our advancing discuss program, data. rapidly generating compelling Let's continues first and which PNH
response suboptimal switchover study with zaltenibart in ravulizumab. a evaluated II Phase to patients PNH Our
from into the patient the As response be trial zaltenibart a further a evaluated the planned improvement, the the having completed open-label baseline therapy all now database PNH. levels. by in of both Results with BLA in to occurred inhibitor, to demonstrating schedule, hemoglobin visit safety building switchover then study the study, in both the of have Patients zaltenibart trial with combination Hematology to in completed significant zaltenibart and switching portion ravulizumab, compared and Congress long-term zaltenibart in therapy adjunctive presented last on trial ravulizumab the European and have receiving reticulocyte statistically included Patients absolute the June Annual were a the for those receiving monotherapy.
The to patients therapy zaltenibart October.
These Association. planned and in began dose CX our study count. in X mean combination patients extension rolled patients demonstrated at
Annual will Diego zaltenibart of at the of Hematology. in the Now data trial from next San the the American presented of monotherapy be stage Society Congress month
as hemoglobin We both are meaningful A continues who have patients profile sustained observed improvements reticulocyte also a counts.
zaltenibart clinically results. monotherapy extravascular as a and with signal absolute the no safety prevented is well intravascular and in PNH safety with been demonstrate hemolysis and complement treated levels to pleased with study showed PNH ongoing, in concern. previously second of favorable not evaluating zaltenibart zaltenibart one inhibitor. this
methodology, program zaltenibart amended study's additional this clinical and quarter's discussed allow analysis until on other our inhibit to and decrease in our the will concentrations protocol occurred, inhibition during that both and generating a aligned breakthrough we've design As that competitor the trial our III plasma with alternative patients data and zaltenibart is already generated agreed resulted MASP-X dose-finding zaltenibart of these European concentrations studies breakthrough in impressive level correlating of our from efficacy program in Phase successful now market program. data support trials. the dose the well III the be for our of our expectation safety patients Phase switchover and that These the selected of with pathway zaltenibart Both And and zaltenibart hemolysis of data to to call, in on successful having treatment-naive regulators on our clinical II have PNH, in zaltenibart earnings required we trial FDA data. Phase last hemolysis.
Based therapeutics.
pivotal Phase program and those FABHALTA PNH and of in trial robust the complement to same efficacy its of show The measures the consists III patients trial other not measures. conducted are are with those endpoint response for CX treatment. receiving in our already used Novartis Specifically, inadequate against inhibitors; who switchover the trials one, an trials by trials: in X results as inhibitor patients zaltenibart our
G-BA, had German both given with by we a successful clear the trials. and have on commercialization, this FDA to that FDA meeting and comments, early treatments regulators. the reimbursed the that held Federal designs incorporated we're that or decision-making In PNH we feedback and care for completed revised Phase we a weeks.
Based of of patient-reported our agreed agencies now Committee, few with European Joint with in few specifies discussions FDA our to body which, our next are measures opening on insurance holidays, the zaltenibart with in will III FDA us in Both underway.
Earlier regulators, studies. the health G-BA is enrollment, also program So successful returned II upcoming which we protocols funds.
The incorporate plan the quarter, statutory health be both within we preparation Phase meetings expect which XXXX. provided a December German path say to we to end outcome the with system pleased productive in the the European medical
through patients differentiate inhibitors. to research and We physicians data zaltenibart that other and from advisory the market will boards solicit also meaningfully continue to input from define complement
the We zaltenibart's are Phase insights per treatment collecting low these the is large to-date, PNH is XXXX non-trial clearly at year, differentiated together with to development.
The other market on and growing, billion trials clinical projected be treatment profile, data III Based from its in Xx in of and X burden billion $X.X only and for XXXX. on in market in options our over activities. to size $XX collected or reported
that approval, its and of resonates zaltenibart prescribers given that substantial differentiated that will command expect We portion patients. well after market with a profile
company of review for rare the CXG, disease CXG. glomerulopathy month, voucher a children. the can any recipient voucher FDA had Let's the first we disease commercially with pediatric subsequent and rare from to The accelerate is X either the designated priority original reduces FDA pediatric for a population. CX new valuable that a indication.
This designation priority different pediatric affecting drug company disease that review treatment this Late voucher or be least be drug's a months. allows indication another product when use. for BLA to a the priority approval it time in entry to for an and can the FDA announced of zaltenibart zaltenibart or review associated at in awarded commonly designation sold holding recipient kidney receive by obtain with turn or or may Companies is application market The a ultra-rare used review drug the by last now
for II is in XXXX. Our is study and program first planned assuming of the Phase data, in a III enrolling zaltenibart CXG CXG half Phase initiation positive
manufactured our and at drug product III and Phase zaltenibart last waiting of call, trials. enrollment and been programs Phase discussed all in III our for ready the As PNH start the has needed quarterly is CXG for
zaltenibart American for activities at with As Omeros groups presentations, and and across alternative pathway abstract Hematology next inhibition. noted of a relevant Society of the Annual have month, the Meeting sizable medical therapeutic including affairs areas earlier, advisory corporate will experts meetings presence and the board
next identify closely of believe do where where So would pathway results with alternative we additional clinical zaltenibart?
Well, follow continue other over we indications advantages have trial substantial to go the we zaltenibart other inhibitors to agents.
at single the on look Omeros' lower are also OMSXXXX, that we next-generation other difficult the diseases the market of inhibition for might medications are this quarterly in driven.
All is that successfully of remember humans targeting long-acting hold keenly specifically take.
Closing subcutaneously could I and which that for patients whether drug therapeutics, efficacy, inhibitor. low-volume both in MASP-X focused discussion on multiple compared MASP-X zaltenibart dosing, particularly that out burden, over our effectively pathology the complement dose alternative exploring better dosing pathway to completed when treatment ascending to often the oral let's of We we advantages significant our convenience safety consistent well intravenously. ablate MASP-X Having are primarily applicability OMSXXXX, the therapeutics wide franchise studies daily to development, be on with administered superior confident more thrice can and remain or Phase concentrations say twice MASP-X with significantly once and or or to compliance and
of the clinical relative, narsoplimab. We across concerns that also shorter-acting with OMSXXXX profile MASP-X no trials its any of compelling, having safety the seen with believe nor OMSXXXX inhibitor is safety the
for of narsoplimab, course, of as additional attractive resource We on availability. dependent, well continue of for assessment indications as OMSXXXX our indications
also in continuing narsoplimab HXNX. well acute and and both as work long syndrome in severe COVID distress We our with inhibition ARDS, or respiratory are as HXNX MASP-X acute and including
the for results prepared detailing manuscripts top-tier study being journals. to again, submission are peer-reviewed Here
In indications. large orally headway OMSXXXX, zaltenibart narsoplimab, in molecule addition market inhibitor to on our chronic programs making use we small MASP-X our continue and MASP-X complement and for available antibodies,
at as Let's turn briefly addictions, treating as PDEX our to compulsions now OMSXXX, well program disorders. inhibitor aimed movement
Institute work to funded for first ongoing fully the remains develop Drug or treatment Abuse, on OMSXXX National use the as Our disorder cocaine NIDA. by
We later cocaine year study assess continue interactions. potential expect exposed OMSXXX and from in results to to and our to rodents primates this drug-drug both toxicology
XXXX, funded the use will previously enrolling dyskinesias evaluating results, treatment. a disease is with satisfactory the profound disorders, Assuming next NIDA.
Also, potential clinical step levodopa-induced use clinical as is or disease, double-blind trial randomized also in trial be prevalent but to the This a highly LID. in OMSXXX of exploring individuals inpatient movement fully are in by its cocaine This by begin we OMSXXX discussed, with problem and in specifically patients by Parkinson's caused rather disorder. not
large pursuing further LID, are funding external and in market. substantial essentially of the development We for a OMSXXX unaddressed
administrations. checkpoint existing also adoptive antibody targeted drug and conjugates like a anticancer meaning adaptive, beyond combination, this, move other radioligands our manufacturing maintains objective programs our complement-mediated unlike simple and beyond to program with are we B and therapy CDX wide such cellular T-cell The conclude an including immunostimulator. of inhibitors review combined engineering, cells today's enhanced both repetitive biologics therapy and and and a immunomodulators, immunostimulator portfolio or requires therapeutic developing therapeutic means cellular with approaches, of and and range targeting as of achieve CAR-T.
To by costs immunotherapies oncotoxins our well T-cell we'll technology therapeutic cellular Building signaling-driven and innate response of time no first-in-class lines T-cells, immune areas, an cancer. an and on Finally, CDX is platform reduces of molecular immunity, and as understanding as
of can broadly both data overcome potential treating CDX currently by of surface deliver safe to therapeutics effector cells. and volume and intracellular shortcomings and therapies and targeting and memory the and marketed in in antigens tumors, of cancer levels the antigen-specific cancer both cancer growing effective solid vivo support vitro hematological that Our and cell CDX increasing
intellectual to property We we oncology expand are continue our programs our rapidly in stealth while development position. advancing
Over experts therapeutic with of under have input area the sought months, and we confidentiality advisers uniformly past response. guidance positive the and several
international the non-confidential these the with Cancer. of Meeting and began we holding in the corporate of Annual Houston past groups at raising Society of academic at Over discussions few programs the congresses, of visibility days, experts Immunotherapy
financial will be a American discussion of our David? Hematology. more We of these to Society our programs turn Accounting previously the of our information publicly go results. share As to team the upcoming mentioned, in months.
I'll over now attending the through to also meeting on call further plan David Borges, coming detailed Officer, the Chief
